Based on the relationship between CEA and type II pneumocyte hyperplasia and lung fibrosis, early medication focuses on atypical epithelial and fibrotic proliferation, such as Nintedanib, may be a potential therapeutic method to decrease the mortality of COVID-19. This evidence concerns the gene CEACAM5 and pulmonary fibrosis.